吉贝尔(688566) - 江苏吉贝尔药业股份有限公司投资者关系活动记录表2024年4月26日

Financial Performance - In 2023, the company achieved a revenue of 860.93 million yuan, representing a year-on-year growth of 31.49% [4] - The net profit attributable to shareholders was 219.09 million yuan, an increase of 41.65% compared to the previous year [4] - The net profit after deducting non-recurring gains and losses was 209.14 million yuan, showing a growth of 49.99% year-on-year [4] - As of December 31, 2023, total assets amounted to 2,209.67 million yuan, with net assets attributable to shareholders at 1,904.84 million yuan [4] Q1 2024 Performance - In Q1 2024, the company reported a revenue of 194.23 million yuan, reflecting a year-on-year increase of 17.47% [4] - The net profit attributable to shareholders for Q1 2024 was 52.51 million yuan, which is a 38.15% year-on-year growth [4] - The stable growth in performance is attributed to enhanced product channel development and increased sales of key products such as Likujun tablets and Nigulol tablets [4] Product Development - The antidepressant drug JJH201501 has completed Phase IIb clinical trials, and Phase III trials are registered with the National Medical Products Administration [5] - The anti-tumor drug JJH201601 has received approval for clinical trials and is currently undergoing Phase I studies [5] - Likujun tablets are recognized for their efficacy in treating leukopenia and are included in the clinical treatment guidelines for malignant tumors [5][6] Innovation and Patents - The company has established a robust R&D team and developed a platform for innovative drug research, focusing on complex formulations and deuterated drugs [4][5] - Multiple patents have been filed to protect the manufacturing methods and formulations of Likujun tablets, ensuring a competitive edge and quality assurance [6]